DGAP-News

EVOTEC AG: 'LAB282' AWARDED FIRST PROJECTS - Seite 3

progressing rapidly to heart failure and death. There is no specific
treatment except for a heart transplant.

The second project, with Dr Ivan Ahel, looks to validate translational
research on DarTG toxin-antitoxin system, a pathway found in tuberculosis.
Essentially a back door around tuberculosis' defences, DarTG could be a
potential target for small molecules, which could shut down the bacteria.
If the project demonstrates that DarTG is the pathogen's Achilles' Heel, it
will pave the way for a new class of antibiotics. Aside from offering a
potential new therapy for tuberculosis, which will become a greater threat
as antibiotic resistance increases, DarTG could also be a weakness in
Escherichia coli, superbug Klebsiella pneumonia, and other gram-negative
pathogens.

ABOUT LAB282

LAB282, initiated in November 2016, is a new £ 13 m partnership between the
Oxford University, Oxford University Innovation Ltd, Oxford Sciences
Innovation plc and Evotec AG created to identify and develop new approaches
to treating serious diseases, which originate from the Oxford University.
The goal is to accelerate the achievement of pre-clinical proof of concept
for new drugs and to generate new spin-out companies. The name derived from
the pantone colour code of "Oxford Blue". For more information, please
visit www.lab282.org.

ABOUT OXFORD UNIVERSITY'S MEDICAL SCIENCES DIVISION
The Division is one of the largest biomedical research centres in Europe,
with over 2,500 people involved in research and more than 2,800 students.
The University is rated the best in the world for medicine, and it is home
to the UK's top-ranked medical school.

From the genetic and molecular basis of disease to the latest advances in
neuroscience, Oxford is at the forefront of medical research. It has one of
the largest clinical trial portfolios in the UK and great expertise in
taking discoveries from the lab into the clinic. Partnerships with the
local NHS Trusts enable patients to benefit from close links between
medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of